BiotechTube
ExeVir

ExeVir

Ghent, Belgium· Est.
exevir.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ExeVir is a private, clinical-stage biotech leveraging a proprietary VHH (single-domain antibody) platform to develop multi-specific antibody therapies against infectious diseases. The company has demonstrated rapid development capabilities, advancing its first candidate from research to clinical trials in under a year. Backed by a strong international investor syndicate and strategic research partnerships, ExeVir is building a pipeline initially targeting COVID-19 and dengue, with the platform holding promise for broader applications in immunology and oncology.

Infectious Diseases

Technology Platform

Modular platform using camelid single-domain antibody fragments (VHH) to create multi-specific, stable, and manufacturable therapeutic constructs with extended half-life potential.

Opportunities

The growing global burden of infectious diseases and the lack of effective therapeutics for targets like dengue present a significant market opportunity.
The company's platform technology allows for rapid response to emerging pandemic threats, positioning it as a potential partner for global health initiatives.

Risk Factors

Key risks include clinical trial failures for novel VHH constructs, intense competition in the infectious disease space (especially for COVID-19), and dependence on raising additional capital to fund later-stage development and commercialization.

Competitive Landscape

ExeVir competes in the infectious disease antibody space with large pharma and numerous biotechs. Its differentiation lies in its multi-specific VHH platform, which aims for broader variant protection and cost-effective production compared to some conventional monoclonal antibodies.

More companies in Biologics / Biosimilars →More companies in Belgium →